MAPT and neurodegenerative disease: In contrast, previous reports have indicated comparable performance of p-Tau217ALZpath and other p-Tau217 assays such as p-Tau217Lilly, p-Tau217Lumipulse and p-Tau217 + Janssen when detecting positivity on Aβ-PET and tau-PET and differentiating AD from other neurodegenerative disease [24, 25, 36].